QQQ   416.98 (-1.52%)
AAPL   165.14 (-1.14%)
MSFT   399.25 (-1.24%)
META   484.04 (-3.54%)
GOOGL   153.51 (-1.60%)
AMZN   174.66 (-2.54%)
TSLA   148.73 (-0.80%)
NVDA   810.37 (-4.29%)
AMD   148.41 (-4.30%)
NIO   3.84 (-4.00%)
BABA   68.67 (-0.30%)
T   16.39 (+0.37%)
F   12.12 (+0.50%)
MU   107.68 (-3.80%)
GE   149.08 (-2.52%)
CGC   8.13 (+3.83%)
DIS   112.03 (-0.36%)
AMC   3.29 (+12.67%)
PFE   25.81 (+1.65%)
PYPL   62.14 (+0.06%)
XOM   120.16 (+1.38%)
QQQ   416.98 (-1.52%)
AAPL   165.14 (-1.14%)
MSFT   399.25 (-1.24%)
META   484.04 (-3.54%)
GOOGL   153.51 (-1.60%)
AMZN   174.66 (-2.54%)
TSLA   148.73 (-0.80%)
NVDA   810.37 (-4.29%)
AMD   148.41 (-4.30%)
NIO   3.84 (-4.00%)
BABA   68.67 (-0.30%)
T   16.39 (+0.37%)
F   12.12 (+0.50%)
MU   107.68 (-3.80%)
GE   149.08 (-2.52%)
CGC   8.13 (+3.83%)
DIS   112.03 (-0.36%)
AMC   3.29 (+12.67%)
PFE   25.81 (+1.65%)
PYPL   62.14 (+0.06%)
XOM   120.16 (+1.38%)
QQQ   416.98 (-1.52%)
AAPL   165.14 (-1.14%)
MSFT   399.25 (-1.24%)
META   484.04 (-3.54%)
GOOGL   153.51 (-1.60%)
AMZN   174.66 (-2.54%)
TSLA   148.73 (-0.80%)
NVDA   810.37 (-4.29%)
AMD   148.41 (-4.30%)
NIO   3.84 (-4.00%)
BABA   68.67 (-0.30%)
T   16.39 (+0.37%)
F   12.12 (+0.50%)
MU   107.68 (-3.80%)
GE   149.08 (-2.52%)
CGC   8.13 (+3.83%)
DIS   112.03 (-0.36%)
AMC   3.29 (+12.67%)
PFE   25.81 (+1.65%)
PYPL   62.14 (+0.06%)
XOM   120.16 (+1.38%)
QQQ   416.98 (-1.52%)
AAPL   165.14 (-1.14%)
MSFT   399.25 (-1.24%)
META   484.04 (-3.54%)
GOOGL   153.51 (-1.60%)
AMZN   174.66 (-2.54%)
TSLA   148.73 (-0.80%)
NVDA   810.37 (-4.29%)
AMD   148.41 (-4.30%)
NIO   3.84 (-4.00%)
BABA   68.67 (-0.30%)
T   16.39 (+0.37%)
F   12.12 (+0.50%)
MU   107.68 (-3.80%)
GE   149.08 (-2.52%)
CGC   8.13 (+3.83%)
DIS   112.03 (-0.36%)
AMC   3.29 (+12.67%)
PFE   25.81 (+1.65%)
PYPL   62.14 (+0.06%)
XOM   120.16 (+1.38%)
Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 1 of 15

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Slide 1
Introduction
Continue to 2
 
Introduction
Continue to 2
 

Novo Nordisk A/S (NYSE:NVO)

Consensus Rating
Moderate Buy
Rating Score
2.8
Ratings Breakdown
6 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$133.60 (8.4% Upside)

About Novo Nordisk A/S

Novo Nordisk A/S logoNovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
4/18/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
4/12/2024BMO Capital MarketsInitiated CoverageOutperform$163.00
4/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
3/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
2/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00
2/14/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00
2/1/2024Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$120.00 ➝ $140.00
1/23/2024Morgan StanleyInitiated CoverageOverweight$120.00
1/16/2024UBS GroupInitiated CoverageNeutral
1/12/2024Cantor FitzgeraldReiterated RatingOverweight
Slide 1
Introduction
Continue to 2
 

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

More From MarketBeat
Healthcare Takes A Big Step Forward With The Help Of AI
from The Bull Report
10 Cheap Stocks Under $10 to Buy Now
from MarketBeat
The “Perfect Storm” for Gold
from Gold Safe Exchange
7 Stocks That Members of Congress Can’t Stop Buying
from MarketBeat
The Best AI Stock to Own in the World Today is Trading for Just $25
from Banyan Hill Publishing
How to Invest In Growth Stocks
from MarketBeat